New Lis­te­ria fears spot­light­ed as Aduro’s CRS-207 is slapped with par­tial hold

Nag­ging fears that Aduro Biotech’s can­cer vac­cine CRS-207 could trig­ger se­ri­ous Lis­te­ria in­fec­tions mush­roomed in­to a se­vere set­back on Mon­day morn­ing as the biotech re­port­ed that it had to halt en­roll­ment in all of its clin­i­cal stud­ies us­ing that tech­nol­o­gy. The par­tial hold was in­sti­tut­ed by the FDA af­ter a pa­tient test­ed pos­i­tive for Lis­te­ria, which is sus­pect­ed to be CRS-207, Aduro’s lead can­cer vac­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA